-
1 month ago | 
neurologylive.com | Robert M. Califf |Marco Meglio
WATCH TIME: 4 minutes"We don’t solve problems as individuals in areas like this—it takes teamwork between scientists, clinicians, patients, and families to make real progress."In recent years, neuromuscular diseases have become a growing focus of investment and innovation, fueled by advances in genetic science, novel therapeutic platforms, and increased public and private funding.
-
2 months ago | 
cgtlive.com | Robert M. Califf |Noah Stansfield
Recent federal funding cuts have significantly affected healthcare organizations, such as the National Institutes of Health (NIH) and the FDA. Concerns have been raised by several leaders of academic institutions that such funding cuts endanger ongoing health research and could hold back innovation in the field.
-
2 months ago | 
cgtlive.com | Robert M. Califf
The former FDA commissioner discussed the necessity of policy and funding efforts for neuromuscular disorders, the stress on the clinical care system, and the need to acknowledge healthcare inequities.
-
2 months ago | 
jamanetwork.com | Leo Anthony Celi |Haider Warraich |Troy Tazbaz |Robert M. Califf
[Skip to Navigation] PDF Full Text Share X Facebook Email LinkedIn Cite Permissions Comment & Response AI in Medicine JAMA. 2025;333(11):1003.
-
Feb 20, 2025 | 
jamanetwork.com | Troy Tazbaz |Robert M. Califf |Haider Warraich
In Reply The US Food and Drug Administration (FDA) is committed to including patient perspectives in the development and evaluation of all medical products, and AI- and machine learning (ML)–enabled products are no different.
-
Jan 17, 2025 | 
jamanetwork.com | Robert M. Califf |Ali Abbasi |Lesley H. Curtis
Consequences and Opportunities From Poor Uptake of COVID Vaccinations Despite Strong Evidence As we enter the winter season of viral illnesses, infections with SARS-CoV-2 (the virus that causes COVID-19), respiratory syncytial virus, and influenza are each on the rise, and there is increasing concern for a pandemic of avian influenza (ie, bird flu) given the enormous animal reservoirs for the virus.
-
Jan 13, 2025 | 
fda.gov | Robert M. Califf
By: Robert M. Califf, M.D., Commissioner of Food and DrugsCOVID-19—the disease caused by the SARS-CoV-2 respiratory virus—has taken a terrible toll. The World Health Organization (WHO) estimates that COVID-19 is responsible for at least 1.2 million deaths in the U.S. and over 7 million deaths worldwide.1 Amid this catastrophic wave of death and remarkably severe illness, multiple emergency policies were enacted at every level of government and in private industry.
-
Nov 15, 2024 | 
jamanetwork.com | Ali Abbasi |Lesley H. Curtis |Robert M. Califf
In Reply The letter by Mr Hauser and Dr Redberg commenting on our recent Special Communication1 on the role of payers in evidence generation raises questions regarding the evidence required at the time products are first approved and who should participate in generating evidence after that point. In our article we did not “propose that it is up to payers [instead of FDA] to ensure that benefits exceed harms” as the letter suggests.
-
Nov 15, 2024 | 
statnews.com | Robert M. Califf |Haider Warraich |Jim Jones
The U.S. Food and Drug Administration is taking a number of steps to help people in the U.S. build healthy diets — including with respect to ultra-processed foods — and the food industry and research community should, too. Ultra-processed foods are usually characterized by industrial processing, the presence of food additives such as flavors or colors, and nutrients intended to make them appetizing (sodium, added sugars, and saturated fat).
-
Nov 5, 2024 | 
fda.gov | Robert M. Califf
By: Robert M. Califf, MD, Commissioner of Food and DrugsNovember 3, 2024, was One Health Day, bringing attention to the pressing need for collaborative solutions for interdependent human, animal, and environmental health concerns.
